Bringing personalized medicine to reproductive health

Offer Fertilome at your clinic

The world’s first comprehensive

genetic screen for reproductive health

Fertilome is a next generation sequencing panel that reveals genetic factors significantly associated with the most common reproductive conditions in women.

Defining a new category of genetic tests

Unlike carrier screening tests, which look at the health risks for a baby, Fertilome is the first genetic screen that examines a woman’s genetic signature and how it may impact her reproductive health and ability to conceive, today and in the future.

How Fertilome can work for you

By revealing genetic risk factors, Fertilome enables more refined diagnoses and treatment decisions than physical examinations or existing diagnostic tests alone. Using Fertilome can help you frame conversations around reproductive health and family building as a proactive journey.

Identify subclinical factors

Refine treatment plans

Counsel women with family history

Counsel egg freezing candidates

Guide targeted lifestyle counseling

The science behind Fertilome

Fertilome analyzes 49 variants in 32 genes associated with a spectrum of female reproductive conditions. The Fertilome panel was developed through a systematic literature review and statistical meta-analysis.

Take the next step

Fertilome is a blood test that can be ordered by a physician. The test is $1,900 out-of-pocket and billed directly to the patient. Fertilome is currently available in all U.S. states. Fertilome is a laboratory developed test run by Celmatix Clinical Laboratories3 and available under the New York State Department of Health's NPL process.4

For physicians

Interested in offering Fertilome at your practice? Contact our team today.

For patients

Interested in asking your provider about Fertilome? Download a discussion guide to share with your physician for ordering.

1. les/2657/current_clinical_validity_classi cations.pdf

2. Fertilome only includes genetic variants that meet the American College of Medical Genetics and Genomics (ACMG) and American Pathology (AMP) 2015 guidelines for pathogenicity of a genetic marker.

MacArthur, DG. et al. Guidelines for investigating causality of sequence variants in human disease. Nature 2014; 508:469-476.

Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17:405-423.

3. Celmatix Clinical Laboratories (CCL) is a high-complexity clinical diagnostics laboratory and is CLIA-certified for compliance, New York State Department of Health (Department) permitted for molecular genetics, and College of American Pathologists (CAP) accredited.

4. Each Fertilome test request must be independently approved by the Department. Department approval should not be considered as an endorsement of CCL's competence; or that CCL has complied with all relevant federal and/or state regulations. The Fertilome genetic test is not currently approved by the Department and is not subjected to approval by the U.S. Food and Drug Administration.